MannKind Corporation Reports Q1 2025 Financial Results: Revenues Rise 18%, Net Income Up 24%, Non-GAAP EPS Increases to $0.07
MannKind Corporation reported Q1 2025 financial results with revenues of $78 million, an 18% increase year-over-year. Net income rose 24% to $13.2 million, and non-GAAP EPS increased to $0.07 from $0.06. Growth was driven by higher demand and pricing for Afrezza, despite a decline in V-Go revenue. The company plans to submit a supplemental Biologics License Application for Afrezza in pediatric patients by mid-2025 and is progressing with its MNKD-101 and MNKD-201 trials.
MannKind Corporation has reported its financial results for the first quarter of 2025, showcasing significant growth in several key areas. The company achieved revenues of $78 million, representing an 18% increase compared to the first quarter of 2024. Net income for the quarter stood at $13.2 million, marking a 24% rise from the same period in the previous year. Additionally, MannKind's non-GAAP net income reached $21.6 million, up 43% from the first quarter of 2024. The company also reported an increase in earnings per share, with a non-GAAP EPS of $0.07 compared to $0.06 in the first quarter of 2024. This growth is attributed to increased net revenue for Afrezza, impacted by higher demand and pricing, although partially offset by a decrease in net revenue for V-Go due to lower demand. In terms of operational updates, MannKind has advanced its pipeline, expecting to submit a supplemental Biologics License Application (sBLA) for Afrezza in pediatric patients by mid-2025. The MNKD-101 global Phase 3 trial for NTM is progressing on track for an interim analysis, and MNKD-201 is expected to continue to the next phase of global development in the second half of 2025.
